These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 28292475)

  • 21. Optimal allocation of HIV resources among geographical regions.
    Kedziora DJ; Stuart RM; Pearson J; Latypov A; Dierst-Davies R; Duda M; Avaliani N; Wilson DP; Kerr CC
    BMC Public Health; 2019 Nov; 19(1):1509. PubMed ID: 31718603
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Should "standard gamble" and "'time trade off" utility measurement be used more in mental health research?
    Flood C
    J Ment Health Policy Econ; 2010 Jun; 13(2):65-72. PubMed ID: 20919593
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Introduction to health economics and decision-making: Is economics relevant for the frontline clinician?
    Goeree R; Diaby V
    Best Pract Res Clin Gastroenterol; 2013 Dec; 27(6):831-44. PubMed ID: 24182604
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Budget impact analysis.
    Leelahavarong P
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S65-71. PubMed ID: 24964701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Multi-Fidelity Rollout Algorithm for Dynamic Resource Allocation in Population Disease Management.
    Ho TY; Liu S; Zabinsky ZB
    Health Care Manag Sci; 2019 Dec; 22(4):727-755. PubMed ID: 30194509
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1.
    Jansen JP; Fleurence R; Devine B; Itzler R; Barrett A; Hawkins N; Lee K; Boersma C; Annemans L; Cappelleri JC
    Value Health; 2011 Jun; 14(4):417-28. PubMed ID: 21669366
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness analysis in relation to budgetary constraints and reallocative restrictions.
    Adang E; Voordijk L; Jan van der Wilt G; Ament A
    Health Policy; 2005 Oct; 74(2):146-56. PubMed ID: 16153475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Guide to an Iterative Approach to Model-Based Decision Making in Health and Medicine: An Iterative Decision-Making Framework.
    Kunst N; Burger EA; Coupé VMH; Kuntz KM; Aas E
    Pharmacoeconomics; 2024 Apr; 42(4):363-371. PubMed ID: 38157129
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A primer on dynamic optimization and optimal control in pharmacoeconomics.
    Vernon JA; Hughen WK
    Value Health; 2006; 9(2):106-13. PubMed ID: 16626414
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1.
    Caro JJ; Briggs AH; Siebert U; Kuntz KM;
    Value Health; 2012; 15(6):796-803. PubMed ID: 22999128
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New type of price measurement for medical services: interest of a cost sensitivity index for a research agenda on pharmaceutical models.
    Huttin CC
    Technol Health Care; 2012; 20(5):463-76. PubMed ID: 23079950
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Economic evaluation in cardiology.
    Maniadakis N; Vardas P; Mantovani LG; Fattore G; Boriani G
    Europace; 2011 May; 13 Suppl 2():ii3-8. PubMed ID: 21518746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--6.
    Briggs AH; Weinstein MC; Fenwick EA; Karnon J; Sculpher MJ; Paltiel AD;
    Value Health; 2012; 15(6):835-42. PubMed ID: 22999133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report.
    Garrison LP; Neumann PJ; Erickson P; Marshall D; Mullins CD
    Value Health; 2007; 10(5):326-35. PubMed ID: 17888097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic aspects of clinical decision making: applications in patient care.
    Oster G
    Am J Hosp Pharm; 1988 Mar; 45(3):543-7. PubMed ID: 3130753
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resource allocation for control of infectious diseases in multiple independent populations: beyond cost-effectiveness analysis.
    Brandeau ML; Zaric GS; Richter A
    J Health Econ; 2003 Jul; 22(4):575-98. PubMed ID: 12842316
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ramsey waits: allocating public health service resources when there is rationing by waiting.
    Gravelle H; Siciliani L
    J Health Econ; 2008 Sep; 27(5):1143-54. PubMed ID: 18468707
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report.
    Ramsey S; Willke R; Briggs A; Brown R; Buxton M; Chawla A; Cook J; Glick H; Liljas B; Petitti D; Reed S
    Value Health; 2005; 8(5):521-33. PubMed ID: 16176491
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force.
    Garrison LP; Towse A; Briggs A; de Pouvourville G; Grueger J; Mohr PE; Severens JL; Siviero P; Sleeper M
    Value Health; 2013; 16(5):703-19. PubMed ID: 23947963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A scoping review of metamodeling applications and opportunities for advanced health economic analyses.
    Degeling K; IJzerman MJ; Koffijberg H
    Expert Rev Pharmacoecon Outcomes Res; 2019 Apr; 19(2):181-187. PubMed ID: 30426801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.